Jolynn Sessions

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint Leukemia. Q&A highlights
    David Frame
    Department of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
    Am J Health Syst Pharm 64:S22. 2007
  2. ncbi request reprint Monitoring your patients with chronic myeloid leukemia
    Jolynn Sessions
    Hematology Oncology, Emory University Hospital, Atlanta, GA 30322, USA
    Am J Health Syst Pharm 63:S5-9; quiz S21-2. 2006
  3. ncbi request reprint Chronic myeloid leukemia in 2007
    Jolynn Sessions
    Hematology Oncology, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA
    Am J Health Syst Pharm 64:S4-9. 2007
  4. ncbi request reprint Chronic myeloid leukemia in 2007
    Jolynn Sessions
    Emory University Hospital, Atlanta, GA, USA
    J Manag Care Pharm 13:4-7. 2007

Detail Information

Publications4

  1. ncbi request reprint Leukemia. Q&A highlights
    David Frame
    Department of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
    Am J Health Syst Pharm 64:S22. 2007
  2. ncbi request reprint Monitoring your patients with chronic myeloid leukemia
    Jolynn Sessions
    Hematology Oncology, Emory University Hospital, Atlanta, GA 30322, USA
    Am J Health Syst Pharm 63:S5-9; quiz S21-2. 2006
    ..Chronic myeloid leukemia (CML), a hematopoietic stem cell disorder, which sometimes presents with fatigue, hepato-splenomegaly, and weight loss but is sometimes asymptomatic, is discussed...
  3. ncbi request reprint Chronic myeloid leukemia in 2007
    Jolynn Sessions
    Hematology Oncology, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA
    Am J Health Syst Pharm 64:S4-9. 2007
    ..Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed...
  4. ncbi request reprint Chronic myeloid leukemia in 2007
    Jolynn Sessions
    Emory University Hospital, Atlanta, GA, USA
    J Manag Care Pharm 13:4-7. 2007
    ..That low mortality rate is due to the availability and efficacy of the new kinase inhibitors that target the BCR-ABL oncogene and other targets to hold disease progression in check...